StockNews.com Initiates Coverage on Evogene (NASDAQ:EVGN)

Investment analysts at StockNews.com started coverage on shares of Evogene (NASDAQ:EVGN) in a research note issued on Thursday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Lake Street Capital lowered their price target on shares of Evogene from $30.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, August 23rd.

Evogene Trading Up 0.4 %

Shares of NASDAQ:EVGN opened at $2.50 on Thursday. The company has a market capitalization of $103.04 million, a price-to-earnings ratio of -5.43 and a beta of 1.40. Evogene has a 12 month low of $2.29 and a 12 month high of $10.40. The firm’s 50-day moving average is $3.16 and its 200 day moving average is $5.37.

Evogene (NASDAQ:EVGN) last released its quarterly earnings data on Thursday, August 22nd. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.94). The company had revenue of $0.91 million during the quarter. Evogene had a negative net margin of 210.26% and a negative return on equity of 72.33%.

Institutional Investors Weigh In On Evogene

An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC acquired a new position in shares of Evogene Ltd. (NASDAQ:EVGN) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Hedge funds and other institutional investors own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.